AC-Selank NH2 (10mg)

Product Details: AC-Selank NH2 (10mg)

AC-Selank NH2 is a lab-synthesized synthetic heptapeptide and a structurally enhanced analog of Selank, an investigational peptide derived from the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg). 

The parent compound Selank incorporates a C-terminal Pro-Gly-Pro (PGP) extension associated with improved metabolic stability in preclinical settings. 

AC-Selank NH2 further introduces N-terminal acetylation and C-terminal amidation. These chemical modifications confer significantly enhanced resistance to aminopeptidase and carboxypeptidase enzymatic hydrolysis. 

Originally investigated as a tuftsin structural analog, AC-Selank NH2 has gained preclinical research interest due to its defined interaction profile across GABAergic, serotonergic, neurotrophic, and immunomodulatory signaling networks. 

This compound is supplied exclusively for controlled laboratory and scientific research purposes and is not intended for any other application.

Mechanism of Action

In preclinical and experimental research settings, AC-Selank NH2 is characterized as a GABAergic allosteric modulator and multi-pathway neuroendocrine signaling research tool. 

Investigational data from studies indicate that the compound engages GABA-A receptor subunit pathways through transcriptional regulation rather than direct receptor binding alone. 

Gene expression analyses demonstrate that Selank analogs alter mRNA levels of GABA receptor subunits, transporters, and ion channel components in cortical tissue in preclinical research settings. [Volkova et al., 2016; Filatova et al., 2017].

Additionally, preclinical investigational findings associate AC-Selank NH2 with the regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in in vitro research settings [Inozemtseva et al., 2008]. 

Serotonergic receptor transcriptional modulation has also been documented in preclinical research, with observed changes in serotonin-related gene expression patterns under controlled experimental conditions [Nadorova et al., 2014].

Properties of AC-Selank NH2 (10mg)

• Molecular Formula: C₃₅H₅₉N₁₁O₁₀
• Molecular Weight: 793.9 g/mol
• CAS Number: J3PM702O93
• Peptide Sequence: Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (TKPRPGP)
• Peptide Class: Synthetic tuftsin-derived neuropeptide analog
• Synonyms: N-Acetyl Selank Amidate; AC-THR-LYS-PRO-ARG-PRO-GLY-PRO; N-Acetyl Selank
• Purity: ≥98.8% (confirmed by third-party analytical testing)
• Form: Lyophilized powder

Research Applications of AC-Selank NH2 (10mg)

GABAergic Signaling Pathway Research 

AC-Selank NH2 is utilized in laboratory settings to investigate allosteric GABA-A receptor subunit modulation. It may also be used to explore gene expression regulation of GABAergic neurotransmission components and downstream inhibitory signaling cascade dynamics in controlled in vitro and preclinical experimental systems.

Neurotrophic Factor Signaling Studies 

Applied in preclinical research settings to examine BDNF and NGF expression pathway regulation, TrkB receptor-mediated neurotrophic signaling activity, and neuroplasticity-related molecular pathway interactions in controlled laboratory environments.

Serotonergic Receptor Transcriptional Modulation Analysis 

It is utilized in experimental research models to explore serotonin receptor gene expression modulation, monoaminergic neurotransmitter signaling network interactions under controlled investigational conditions.

Immunomodulatory Cytokine Signaling Research

Research suggested that the compound may serve as a tuftsin-derived research tool for analyzing IL-6 and TNF-alpha cytokine expression pathway modulation, neuroimmune signaling network interactions, and pro- and anti-inflammatory cytokine balance regulation in controlled preclinical research settings.

Peptide Stability and Enzymatic Degradation Research 

Used in controlled laboratory environments to study N-terminal acetylation and C-terminal amidation effects on aminopeptidase and carboxypeptidase resistance. It is also used to study comparative peptide degradation kinetics and extended receptor interaction profiles relative to unmodified parent peptide compounds.

Why Choose BehemothLabz to Buy AC-Selank NH2 (10mg)?

BehemothLabz is committed to providing high-purity research peptides manufactured under strict quality control standards. Each batch of AC-Selank NH2 undergoes independent third-party analytical testing to confirm identity, purity, and consistency. 

With a focus on transparency and scientific reliability, BehemothLabz supports researchers with dependable compounds suitable for advanced laboratory and preclinical investigations. Competitive pricing, secure payment processing, and domestic and international shipping availability further support researchers at every level.

Support is direct: support@behemothlabz.com | (307) 429-0990

Disclaimer

This compound is not approved by the U.S. Food and Drug Administration (FDA) for any purpose. It is provided strictly for laboratory and scientific research purposes only. Clinical research initiatives must be conducted under IRB guidance; preclinical studies must comply with IACUC directives under the Animal Welfare Act (AWA). Not for any form of administration outside of controlled laboratory research settings.

Please make sure you review the Terms and Conditions and familiarize yourself with them prior to purchasing. Please research the scientific uses of this product before placing any orders. Please note that the packaging and labels of the product may differ from those shown on the website.

FAQs

Is AC-Selank NH2 legal in the United States? 

AC-Selank NH2 (CAS 2212313-10-6) is a research chemical not approved by the FDA for use outside of controlled laboratory settings. It is legal to purchase in the United States exclusively for laboratory research purposes. It is not approved for human or veterinary administration under any circumstance. 

How does AC-Selank NH2 differ from the parent compound Selank? 

AC-Selank NH2 introduces two terminal modifications absent from the parent compound Selank: N-terminal acetylation and C-terminal amidation. In preclinical research settings, these modifications confer significantly enhanced resistance to aminopeptidase and carboxypeptidase enzymatic hydrolysis compared to the unmodified parent peptide, producing an extended investigational activity profile in controlled experimental systems. 

What signaling pathways is AC-Selank NH2 investigated for in preclinical research?

Preclinical investigational data associate AC-Selank NH2 with modulation of GABA-A receptor subunit gene expression, regulation of BDNF and NGF neurotrophic factor pathways, transcriptional changes in serotonergic receptor systems, and attenuation of IL-6 and TNF-alpha cytokine signaling cascades in controlled in vitro and in vivo preclinical research settings. 

What does the published research on Selank analogs show regarding GABAergic neurotransmission? 

Gene expression analyses published by Volkova et al. (2016) and Filatova et al. (2017) document that Selank analogs alter mRNA levels of GABA receptor subunits, transporters, and ion channel components in cortical tissue under controlled preclinical conditions. These findings are cited for receptor pharmacology context only and document research conducted on the parent compound Selank, not AC-Selank NH2 specifically. [Cited for receptor pharmacology context only. Documents preclinical research on the parent compound Selank and does not apply to the research-grade AC-Selank NH2 formulation supplied here.] 

What are the storage and handling requirements for AC-Selank NH2? 

AC-Selank NH2 is supplied as a lyophilized powder with a confirmed 2-year shelf life under recommended storage conditions. Store at –20°C or below, protected from light and moisture. Once reconstituted, aliquot immediately to minimize freeze-thaw degradation and do not store reconstituted solution at ambient temperature. 

Reference Links

Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology, 7, 31. https://pubmed.ncbi.nlm.nih.gov/26924987/

Filatova, E., Kasian, A., Kolomin, T., Rybalkina, E., Alieva, A., Andreeva, L., Limborska, S., Myasoedov, N., Pavlova, G., Slominsky, P., & Shadrina, M. (2017). GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Frontiers in Pharmacology, 8, 89. https://pubmed.ncbi.nlm.nih.gov/28293190/

Inozemtseva, L. S., Karpenko, E. A., Dolotov, O. V., Levitskaya, N. G., Kamensky, A. A., Andreeva, L. A., & Grivennikov, I. A. (2008). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences, 421, 241–243. https://pubmed.ncbi.nlm.nih.gov/18841720/

Nadorova, A. V., Kolik, L. G., Klodt, P. M., Narkevich, V. B., Naplyokova, P. L., Kozlovskaya, M. M., & Kudrin, V. S. (2014). The relationship between the anxiolytic action of Selank and the level of serotonin in brain structures during the modeling of alcohol abstinence. Neurochemical Journal, 8(2), 115–120. https://pubmed.ncbi.nlm.nih.gov/24860328/